CLAIMS

What is claimed is:

1. A crystalline salt of 2-(*tert*-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, wherein the crystalline salt is a hydrochloride salt, a sulfate salt, a phosphate salt, an L-tartrate salt, or an L-lactate salt.

2. A pharmaceutical composition comprising the crystalline salt of claim 1.

3. A dosage form comprising the crystalline salt of claim 1.

4. The pharmaceutical composition of claim 2 or the dosage form of claim 3, wherein said pharmaceutical composition or said dosage form is a tablet.

5. A crystalline salt according to claim 1, a pharmaceutical composition according to claim 2 or 4, or a dosage form according to claim 3 or 4 for use in a method for treating or preventing a disease or disorder treatable or preventable by inhibition of a JNK pathway, wherein said disease or disorder is selected from a group consisting of interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection and lupus; or
wherein said disease or disorder is a liver fibrotic disorder, diabetes or a metabolic syndrome leading to lover fibrotic disorders.

6. Use of a crystalline salt according to claim 1, a pharmaceutical composition according to claim 2 or 4, or a dosage form according to claim 3 or 4 in the manufacture of a medicament for treating or preventing a disease or disorder treatable by inhibition of a JNK pathway,
wherein said disease or disorder is selected from a group consisting of interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection and lupus; or
wherein said disease or disorder is a liver fibrotic disorder, diabetes or a metallic syndrome leading to liver fibrotic disorders.